Physician profile
Robert G Samaan
NPI 1265482871
$10,498.62
in general payments reported to CMS, 2019-2025
43 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,264 · 2020: $2,006 · 2021: $1,477 · 2022: $1,180 · 2023: $1,314 · 2024: $1,206 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,563.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,012.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $805.84 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $755.21 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $711.09 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $622.29 | 2019-2022 | |
| Amarin Pharma, INC. | $621.89 | 2019-2023 | |
| Pfizer INC. | $581.96 | 2019-2025 | |
| Novo Nordisk INC | $577.31 | 2019-2023 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $402.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $391.15 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.46 | 2021-2025 | |
| Esperion Therapeutics, INC. | $247.81 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $246.95 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $201.08 | 2019-2025 | Zoryve |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Samaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.